1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Can Lynparza Hold On As PARP Inhibitors Enter First-Line Prostate Cancer Market?

 
• By Alaric DeArment

AstraZeneca, Pfizer and Johnson & Johnson are presenting Phase III data for PARP inhibitors combined with anti-androgen drugs in first-line mCRPC, a potential blockbuster opportunity.

AZ Cambridge campus
AstraZeneca - along with Pfizer and J&J - presented Phase III PARP inhibitor data in first-line prostate cancer at ASCO GU • Source: Shutterstock

Data from three Phase III studies presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) give a preview of what is set to become a highly competitive field for PARP inhibitors combined with anti-androgen drugs in first-line metastatic castration-resistant prostate cancer (mCRPC). With its more established position in the field, AstraZeneca PLC’s Lynparza (olaparib) may retain a competitive edge, but the space looks likely to become a three-way competition between it, Pfizer Inc.’s Talzenna (talazoparib) and Johnson & Johnson/GSK plc’s Zejula (niraparib).

ASCO GU included presentations on 16 February from three Phase III studies in particular: the PROpel trial of Lynparza combined...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

Exelixis Positions Zanzalintinib For Post-Cabozantinib LOE Future

 
• By Alaric DeArment

The company announced positive Phase III data in previously treated colorectal cancer for zanzalintinib and it could see sales of more than $1bn in that indication.

J&J’s Trispecific Antibody For Myeloma Offers Improved Safety, Potency Over Bispecifics

 
• By Alaric DeArment

The drugmaker presented data from its Phase I study of JNJ-79635322 at ASCO and EHA showing a 100% response rate in BCMA- and GPRC5D-naïve patients.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Immuneering Could Partner Atebimetinib Or Go It Alone After Phase IIa Success

 
• By Alaric DeArment

CEO Ben Zeskind said all options are on the table after atebimetinib showed impressive results in pancreatic cancer.

More from Therapy Areas

Merck & Co.’s Winrevair Positioned For Expansion On HYPERION Results

 
• By Jessica Merrill

The Phase III trial met the primary endpoint of time to clinical worsening in patients newly diagnosed with pulmonary arterial hypertension.

Novo And Lilly Lay Out Patient Segmentation Plans For Obesity Treatment

 
• By Andrew McConaghie

As competition heats up and the obesity market matures, the two frontrunners are tailoring their studies to the wants and needs of different patient groups.

Vertex Heralds ‘Unprecedented’ Zimislecel Type 1 Diabetes Data

 
• By Kevin Grogan

The off-the-shelf stem cell therapy shows sustained glycemic control and a high rate of insulin independence.